EXHIBIT 99.1







|For Release: Thursday, July 20, 2006, 3:05 pm Central Time | NEWS RELEASEContact: Howard Root, CEO
James Hennen, CFOVascular Solutions, Inc.
(763) 656-4300
|---------------------------------------------------------- | ----------------------------------------------------------------------------------------------

VASCULAR SOLUTIONS ANNOUNCES SECOND QUARTER NET SALES

UP 35% TO RECORD $10.9 MILLION AND RAISES 2006 GUIDANCE



Each major product line contributed to 10% sequential quarterly sales growth



MINNEAPOLIS, Minnesota -- Vascular Solutions, Inc. (Nasdaq:VASC) today announced
record revenue for the second quarter ended June 30, 2006 of $10.9 million, a
35% increase over the $8.1 million recorded in the second quarter of 2005. On a
sequential basis, net sales increased 10% from the first quarter of 2006.



The second quarter of 2006 represented the companys tenth consecutive
quarter of record net sales. Growth in each major product line contributed to
the increase in revenue. In total, over 86% of net sales in the second quarter
came from sales of new product lines Vascular Solutions has internally developed
and launched in the U.S. since 2003.



The resulting net loss for the second quarter was $653,000 or $0.04 per share,
compared to net income of $75,000 or $0.00 per share in the second quarter of
2005. During the second quarter of 2006 the company incurred $952,000 in
expenses related to the development and qualification of a new supply of
thrombin, a primary component of its hemostatic products, and $316,000 of
stock-based compensation expense. As adjusted (excluding the thrombin
qualification expenses, stock-based compensation expense and assuming a tax rate
of 39%) net income was $375,000 or $0.02 per fully diluted share in the second
quarter of 2006, increasing from adjusted net income of $131,000 or $0.01 per
fully diluted share in the second quarter of 2005. The second quarter of 2006
represented the companys sixth successive quarter of adjusted net
income.



Commenting on second quarter results, Vascular Solutions Chief Executive Officer
Howard Root said: Following an excellent first quarter, in the second
quarter we once again demonstrated outstanding sales growth led by our two
largest product lines, the D-Stat Dry hemostatic bandage and the
Pronto extraction catheter. Similar to the first quarter, the overall
result was revenue that exceeded the upper end of our guidance. Importantly, we
continue to manage the qualification of our new source of thrombin within our
timing and budget requirements, and we continue to believe that our current
working capital and line of credit are adequate for all of our future capital
needs. Building off this progress, we expect to continue to set new quarterly
sales records each quarter for the foreseeable future.



Net sales of the D-Stat Dry product line were $4.3 million during the second
quarter, an increase of 26% over the second quarter of 2005. O
ur D-Stat Dry product line showed continued quarterly
growth, with a gain of $261,000, or 6%, sequentially from the first quarter of
2006, commented Mr. Root. Looking forward, we believe
that the product line extensions of the ThrombiGel® and other new versions
in development will result in continued increases in sales of the D-Stat Dry
product line throughout the remainder of 2006.

---

Net sales of the Pronto extraction catheter totaled $2.3 million in the second
quarter, an increase of 41% over the second quarter of 2005 and 12% sequentially
from the first quarter. In the second quarter we saw new competition in
the U.S. market for extraction catheters, and we were able to meet the
competition and continued to grow sales of our V3 version due to its superior
performance characteristics, commented Mr. Root.



Net sales of the Vari-Lase® endovenous laser product line totaled $1.6
million in the second quarter, an increase of 59% over the second quarter of
2005 and 14% sequentially from the first quarter. Net sales of the disposable
products within the Vari-Lase product line increased 86% in the second quarter
of 2006 over the second quarter of 2005 and 24% sequentially from the first
quarter. Our improvements in the new completely custom
disposable offering have been favorably received by our customers,
commented Mr. Root. Even more important, our direct sales force has
shown the coverage, support and consistency necessary to satisfy the competitive
requirements of endovenous laser therapy customers, Mr. Root
added.



Net sales of specialty catheters, which consist of the Langston® dual lumen
catheters, Twin-Pass dual access and Skyway support catheters, were
$846,000 in the second quarter of 2006, an increase of 374% over the second
quarter of 2005. Our specialty catheters have now become the fourth major
product line for Vascular Solutions, commented Mr. Root. The
new Twin-Pass has been received very well, and we have several additional
products working through our development process that should add to the
outstanding growth in the specialty catheter product line through 2006 and into
2007, added Mr. Root.



Net sales of access products, which consist of micro-introducers and specialty
guidewires, totaled $369,000 in the second quarter, an increase of 155% over the
second quarter of 2005 and 19% sequentially from the second quarter. The
access product line has outstanding growth potential which we are only beginning
to realize, commented Mr. Root. This product line is expected
to grow substantially with broader sales activities and several new products
being introduced within the next year, Mr. Root added



Net sales of the D-Stat® Flowable hemostat were $671,000 in the second
quarter of 2006, an increase of 31% over the second quarter of 2005. We
expect the D-Stat Flowable to continue to grow modestly with its current
indications for use, commented Mr. Root. Driving future growth
will be the pocket protector indication of the Flowable for use in
pacemaker and ICD implants which we now have pending with the FDA and addresses
a potential $10 million annual market.



Net sales of the Duett sealing device totaled $570,000 in the second
quarter of 2006. We continue to support and harvest our Duett
product line with our existing customers, resulting in the expected decline in
sales, commented Mr. Root.



Overall gross margin across all products was 67% in the second quarter of 2006,
in line with expectations, but down from 71% in the second quarter of 2005. The
gross margin decrease was principally due to the growth in sales of products
other than the D-Stat Dry, which has a substantially higher gross margin than
the other products, and the conversion to the Pronto V3, which has a higher
manufacturing cost than the original Pronto. Gross margins also were negatively
affected by the addition of the new stock-based compensation expense. Based on
projected increased sales of the V3, planned manufacturing cost improvements and
the inclusion of stock-based compensation, gross margins for the remainder of
2006 are expected to increase to between 68% and 69%.

---

During the second quarter, development and qualification of a new source of
thrombin for use in the companys hemostatic products also continued.
In the second quarter we received conditional approval from the FDA to
commence our clinical study, and we remain on track for the approval of the use
of our thrombin in our hemostatic products by mid-2007. Our current supply of
approved thrombin is projected to last us into 2008 under current sales
forecasts, commented Mr. Root.



The company also issued guidance for the third quarter of 2006 and raised its
2006 annual sales guidance. Net sales in the third quarter are expected to
increase to between $11.0 million and $11.5 million, at least a 28% increase
over the third quarter of 2005. Due to the outstanding performance of the
first two quarters, it is now reasonable to raise guidance for 2006 sales to
between $43.5 million and $44.5 million. Longer term, net sales are expected to
continue to increase by at least 25% annually over the next several years. We
continue to believe that our strategy of internally developing a variety of new
clinically-based products sold by our focused direct sales force to our existing
customers will allow us to achieve our next long term milestone, which is $100
million in annual sales, concluded Mr. Root.



Conference Call & Webcast Information



Vascular Solutions will host a live webcast starting at 3:30 p.m., Central Time
today to discuss the information contained in this press release. The live web
cast may be accessed on the investor relations portion of our web site at
www.vascularsolutions.com. Web participants are encouraged to go to the
web site at least 15 minutes prior to the start of the call to download and
install any necessary audio software. An audio replay of the call will be
available until Thursday, August 3, 2006 by dialing 1-800-642-1687 and entering
conference ID #2483573. A recording of the call will also be archived on the
investor relations portion of the Companys web site,
www.vascularsolutions.comuntil Thursday, August 3, 2006. During the
conference call the Company may answer one or more questions concerning business
and financial developments and trends, the Companys view on earnings
forecasts and new product development and financial matters affecting the
Company, some of the responses to which may contain information that has not
been previously disclosed.

---

VASCULAR SOLUTIONS, INC.

CONDENSED STATEMENTS OF OPERATIONS





|Three Months Ended
June 30,                           |  | Six Months Ended
June 30,
|----------------------------------------------------- |  | -------------------------
|
|
|                                                     
|Net sales                                             |  |                          
|Cost of goods sold (1)                                |  |                          
|                                                      |  |                          
|Gross profit                                          |  |                          
|                                                     
|Operating expenses:                                   |  |                          
|Research and development (1)                          |  |                          
|Clinical and regulatory (1)                           |  |                          
|Sales and marketing (1)                               |  |                          
|General and administrative (1)                        |  |                          
|Thrombin qualification                                |  |                          
|Amortization of purchased technology                  |  |                          
|                                                      |  |                          
|                                                     
|Operating income (loss)                               |  |                          
|Interest expense                                      |  |                          
|Interest income                                       |  |                          
|                                                      |  |                          
|Net income (loss)                                     |  |                          
|                                                      |  |                          
|                                                     
|Net income (loss) per share - basic                   |  |                          
|                                                      |  |                          
|Weighted average shares used in calculating - basic   |  |                          
|                                                      |  |                          
|Net income (loss) per share - diluted                 |  |                          
|                                                      |  |                          
|Weighted average shares used in calculating - diluted |  |                          
|                                                      |  |                          
|                                                     
|(1) Includes stock-based compensation charges of:     |  |                          
|Costs of goods sold                                   |  |                          
|Research and development                              |  |                          
|Clinical and regulatory                               |  |                          
|Sales and marketing                                   |  |                          
|General and administrative                            |  |                          
|                                                      |  |                          
|                                                      |  |                          

---

VASCULAR SOLUTIONS, INC.

CONDENSED BALANCE SHEETS



|                                           |  | June 30,2006(unaudited) |   | December 31,2005(note)
|------------------------------------------ |  | ----------------------- | - | ----------------------
|ASSETS                                     |  |                         |   |                       
|Current assets:                            |  |                        
|Cash and cash equivalents                  |  |                         | $ | 2,226                 
|Accounts receivable, net                   |  |                         |   | 6,100                 
|Inventories                                |  |                         |   | 8,045                 
|Prepaid expenses                           |  |                         |   | 536                   
|                                           |  |                         |   |                       
|Total current assets                       |  |                         |   | 16,907                
|Property and equipment, net                |  |                         |   | 3,273                 
|Intangible assets                          |  |                         |   | 193                   
|                                           |  |                         |   |                       
|Total assets                               |  |                         | $ | 20,373                
|                                           |  |                         |   |                       
|                                          
|LIABILITIES AND SHAREHOLDERS EQUITY       |  |                        
|Current liabilities:                       |  |                        
|Total current liabilities                  |  |                         | $ | 5,327                 
|                                          
|Long-term debt                             |  |                         |   | 1,267                 
|                                          
|Shareholders equity:                      |  |                        
|Total shareholders equity                 |  |                         |   | 13,779                
|                                           |  |                         |   |                       
|Total liabilities and shareholders equity |  |                         | $ | 20,373                
|                                           |  |                         |   |                       

Note: Derived from the audited financial statements at that date.



Use of Non-GAAP Measures



Management uses non-GAAP measures to establish operational goals, and believes
that non-GAAP measures may assist investors in analyzing the underlying trends
in the Companys business over time. Investors should consider these
non-GAAP measures in addition to, not as a substitute for or as superior to,
financial reporting measures prepared in accordance with GAAP. In this press
release, the Company has reported a non-GAAP measure called adjusted net income
which excludes certain expenses relating to the qualification of a new supply of
thrombin and stock-based compensation, but includes assumed taxes on net income
using a 39% tax rate. On October 18, 2004, the Company entered into a supply
agreement with Sigma-Aldrich Fine Chemicals for the development, manufacture and
supply of bulk thrombin for use in the Companys hemostatic products. The
Company estimates that the development and qualification of this new supply of
thrombin will be completed in 2007, with estimated expenditures through the end
of 2006 expected to be approximately $5.3 million in operating expenses, $1.7
million in inventory and $0.8 million in capital equipment purchases. The
Company has incurred approximately $3.5 million of the operating expenses, all
of the capital purchases and all of the inventory expenditures through June 30,
2006. Management believes that although the qualification expenses are a
recurring cost, it is useful to exclude them from net income given the short
duration of these expenses and the expectation that similar expenses will not
need to be incurred for the foreseeable future. Beginning January 1, 2006 the
Company recognizes stock-based compensation expense, which has been excluded
from adjusted net income to provide comparable financial information to prior
periods. In the second quarter of 2006 the Company incurred stock-based
compensation expense of $316,000. Management uses the adjusted net income
measure in its internal analysis and review of operational performance.
Management includes the thrombin

---

qualification expenses as well as the related inventory and capital equipment
purchases in its cash projections. Management believes that this adjusted net
income measure provides investors with useful information in comparing the
Companys performance over different periods, particularly when comparing
this period to periods in which the Company did not incur any expenses relating
to these expenses. By using this non-GAAP measure management believes that
investors get a better picture of the performance of the Companys
underlying business. Management encourages investors to review the
Companys net income prepared in accordance with GAAP to understand the
Companys performance taking into account all relevant factors, including
those that may only occur from time to time but have a material impact on the
Companys financial results.



About Vascular Solutions



Vascular Solutions, Inc. is a medical device company that focuses on developing
unique solutions for unmet clinical opportunities within Interventional
radiology and Interventional cardiology. New products introduced since the
second half of 2003 include the Vari-Lase® endovenous laser product line for
the treatment of varicose veins, the D-Stat Dry hemostatic bandage for the
rapid control of topical bleeding, the Pronto extraction catheter for the
mechanical extraction of soft thrombus, the Langston® dual lumen catheter
for the measurement of aortic stenosis and the Twin-Pass dual access
catheter for dual wire access in interventional procedures. The Companys
other major products include the Duett sealing device to rapidly seal the
puncture site following catheterization procedures and the D-Stat® Flowable
hemostat for the local management of active bleeding.



The information in this press release contains forward-looking statements that
involve risks and uncertainties. Our actual results could differ materially from
those anticipated in these forward-looking statements. Important factors that
may cause such differences include those discussed in our Annual Report on Form
10-K for the year ended December 31, 2005 and other recent filings with the
Securities and Exchange Commission. The risks and uncertainties include, without
limitation, risks associated with the need for adoption of our new products,
limited working capital, lack of profitability, exposure to intellectual
property claims, dependence on key vendors, exposure to possible product
liability claims, the development of new products by others, doing business in
international markets, limited manufacturing experience, the availability of
third party reimbursement, and actions by the FDA.



For further information, connect to www.vascularsolutions.com.

# # #

---